Study Evaluating MYO-029 in Adult Muscular Dystrophy

Completed · Phase 1/Phase 2

Conditions studied: Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy

In brief

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Key facts

Study ID

NCT00104078

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

108

Starts

2005-02-01

Expected to finish

2007-01-01

Last updated by the study team

2007-12-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent.
• Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)
• Independently ambulatory

You may not qualify if…

• Patients with certain clinical conditions
• Patients using steroids or other medications with the potential to affect muscle function
• History of sensitivity to monoclonal antibodies or protein pharmaceuticals
• Pregnant or lactating women.

Where it is running

• Study site — Washington D.C., District of Columbia, United States
• Study site — Kansas City, Kansas, United States
• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — St Louis, Missouri, United States
• Study site — Rochester, New York, United States
• Study site — Columbus, Ohio, United States
• Study site — Dallas, Texas, United States
• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.